Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 617-630

  Ichikawa, Yoshihiko ^a   Ghanefar, Mohsen ^a   Bayeva, Marina ^a   Wu, Rongxue ^a   Khechaduri, Arineh ^a   Naga Prasad, Sathyamangla V ^b   Mutharasan, R Kannan ^a   Jairaj Naik, Tejaswitha ^a   Ardehali, Hossein ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOTONIC AGENTS; CROSSES, GENETIC; DEFEROXAMINE; DEXRAZOXANE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; HEMODYNAMICS; HUMANS; IRON; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TOPOISOMERASE II INHIBITORS;

EID: 84893845965     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72931     Document Type: Article

References (53)

1. Binaschi M, et al. Anthracyclines: selected new developments. Current medicinal chemistry. Curr Med Chem Anticancer Agents. 2001;1(2):113-130.
2. Ferrans VJ, Clark JR, Zhang J, Yu ZX, Herman EH. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia. 1997;39(10):928-937.
3. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5(6):791-809.
4. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154-171.
5. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23(1):15-25.
6. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Seminars in oncology. 1998; 25(4 suppl 10):10-14.
7. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47(2):219-231.
8. Myers CE, Gianni L, Simone CB, Klecker R, Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry. 1982;21(8):1707-1712.
9. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68(2):261-271.
10. Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol. 2007;49(25):2457-2464.
11. Miranda CJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood. 2003;102(7):2574-2580.
12. Hasinoff BB, Herman EH. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol. 2007;7(2):140-144.
13. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 2004;130(1):1-7.
14. Herman EH, Ferrans VJ. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat Rev. 1990;17(2-3):155-160.
15. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68(2):261-271.
16. Higgins CF, Linton KJ. ABC transporters: An introduction and overview. In: Holland IB, Cole SP, Kuchler K, Higgins CF, eds. ABC Proteins: From Bacteria to Man. San Diego, California, USA: Academic Press; 2003: xvii-xxii.
17. Ichikawa Y, et al. Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc Natl Acad Sci U S A. 2012;109(11):4152-4157.
18. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003; 3(2):89-99.
19. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol. 1996;271(5 pt 2):H2079-H2085.
20. Marechal X, et al. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clin Sci (Lond). 2011;121(9):405-413.
21. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003;23(3B):2445-2450.
22. Kwok JC, Richardson DR. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol. 2002;62(4):888-900.
23. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001; 61(23):8422-8428.
24. Petrat F, Weisheit D, Lensen M, de Groot H, Sustmann R, Rauen U. Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor. Biochem J. 2002;362(pt 1):137-147.
25. Rauen U, et al. Assessment of chelatable mitochondrial iron by using mitochondrion-selective fluorescent iron indicators with different iron-binding affinities. Chembiochem. 2007;8(3):341-352.
26. Elihu N, Anandasbapathy S, Frishman WH. Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol. 1998;38(2):101-105.
27. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85(2):393-400.
28. Ihnat PM, Vennerstrom JL, Robinson DH. Synthesis and solution properties of deferoxamine amides. J Pharm Sci. 2000;89(12):1525-1536.
29. Lipshultz SE, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: longterm follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961.
30. Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-1642.
31. Rao VA. Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. Antioxid Redox Signal. 2013;18(8):930-955.
32. Lyu YL, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-8846.
33. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1998;1400(1-3):155-171.
34. Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001;59(3):453-461.
35. Neufeld EJ. Update on iron chelators in thalassemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2010;2010:451-455.
36. Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol. 1994;35(2):93-100.
37. Hershko C, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. The J Lab Clin Med. 1993; 122(3):245-251.
38. Zanninelli G, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51(5):842-852.
39. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35(11):1469-1479.
40. Popelova O, et al. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther. 2008;326(1):259-269.
41. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol. 2003;63(4):849-861.
42. Xu X, Sutak R, Richardson DR. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol Pharmacol. 2008; 73(3):833-844.
43. Rao VA. Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. Antioxid Redox Signal. 2013;18(8):930-955.
44. Martin E, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009;255(1-2):72-79.
45. Swain SM, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-1332.
46. Tebbi CK, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007; 25(5):493-500.
47. Salzer WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2010;24(2):355-370.
48. MHRA. Dexrazoxane (Cardioxane): restriction of use to adults with advanced or metastatic breast cancer only. Drug Safety Update. 2011;4(12):A3.
49. Tangeras A, Flatmark T, Backstrom D, Ehrenberg A. Mitochondrial iron not bound in heme and iron-sulfur centers. Estimation, compartmentation and redox state. Biochim Biophys Acta. 1980; 589(2):162-175.
50. Gordon LI, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284(4):2080-2087.
51. Ardehali H, Xue T, Dong P, Machamer C. Targeting of the mitochondrial membrane proteins to the cell surface for functional studies. Biochem Biophys Res Commun. 2005;338(2):1143-1151.
52. Albert Y, Whitehead J, Eldredge L, Carter J, Gao X, Tourtellotte WG. Transcriptional regulation of myotube fate specification and intrafusal muscle fiber morphogenesis. J Cell Biol. 2005;169(2):257-268.
53. Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta. 1985;817(1):193-196.